Gepride M 4 Forte Tablet PR contains a combination of Glimepiride 4 mg and Metformin 1000 mg, formulated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization. This dual mechanism provides effective glycemic control in patients inadequately controlled by diet and exercise alone. Gepride M 4 Forte Tablet PR is indicated as an adjunct to lifestyle modifications for adults with type 2 diabetes, particularly when monotherapy with either agent is insufficient. The prolonged-release formulation ensures a steady plasma concentration, improving patient compliance and minimizing gastrointestinal side effects commonly associated with Metformin. It is essential to monitor renal function prior to and during therapy, as Metformin is contraindicated in patients with significant renal impairment due to the risk of lactic acidosis. Caution is advised in patients with hepatic dysfunction, cardiovascular disease, or conditions predisposing to hypoxia. Dosage adjustments should be individualized based on glycemic response and tolerability. Regular monitoring of blood glucose and HbA1c levels is recommended to optimize therapeutic outcomes. Gepride M 4 Forte Tablet PR should be used under medical supervision with appropriate lifestyle interventions.